198 related articles for article (PubMed ID: 32529758)
1. Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region.
Goudsmit BFJ; Putter H; Tushuizen ME; de Boer J; Vogelaar S; Alwayn IPJ; van Hoek B; Braat AE
Am J Transplant; 2021 Jan; 21(1):229-240. PubMed ID: 32529758
[TBL] [Abstract][Full Text] [Related]
2. Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.
Goudsmit BFJ; Putter H; Tushuizen ME; Vogelaar S; Pirenne J; Alwayn IPJ; van Hoek B; Braat AE
Hepatology; 2021 Jul; 74(1):351-363. PubMed ID: 33301607
[TBL] [Abstract][Full Text] [Related]
3. MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List.
Asrani SK; Jennings LW; Kim WR; Kamath PS; Levitsky J; Nadim MK; Testa G; Leise MD; Trotter JF; Klintmalm G
Hepatology; 2020 May; 71(5):1766-1774. PubMed ID: 31523825
[TBL] [Abstract][Full Text] [Related]
4. Model for end-stage liver disease-sodium and survival benefit in liver transplantation.
Vitale A; Bertacco A; Gambato M; D'Amico F; Morales RR; Frigo AC; Zanus G; Burra P; Angeli P; Cillo U
Transpl Int; 2013 Feb; 26(2):138-44. PubMed ID: 23194386
[TBL] [Abstract][Full Text] [Related]
5. Joint modeling of liver transplant candidates outperforms the model for end-stage liver disease: The effect of disease development over time on patient outcome.
Goudsmit BFJ; Braat AE; Tushuizen ME; Vogelaar S; Pirenne J; Alwayn IPJ; van Hoek B; Putter H
Am J Transplant; 2021 Nov; 21(11):3583-3592. PubMed ID: 34174149
[TBL] [Abstract][Full Text] [Related]
6. Superiority of the new sex-adjusted models to remove the female disadvantage restoring equity in liver transplant allocation.
Marrone G; Giannelli V; Agnes S; Avolio AW; Baiocchi L; Berardi G; Ettorre GM; Ferri F; Corradini SG; Grieco A; Guglielmo N; Lenci I; Lionetti R; Mennini G; Milana M; Rossi M; Spoletini G; Tisone G; Manzia TM; Lai Q
Liver Int; 2024 Jan; 44(1):103-112. PubMed ID: 37752798
[TBL] [Abstract][Full Text] [Related]
7. Region 11 MELD Na exception prospective study.
Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
[TBL] [Abstract][Full Text] [Related]
8. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.
Somsouk M; Kornfield R; Vittinghoff E; Inadomi JM; Biggins SW
Liver Transpl; 2011 Feb; 17(2):129-36. PubMed ID: 21280185
[TBL] [Abstract][Full Text] [Related]
9. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.
Nagai S; Chau LC; Schilke RE; Safwan M; Rizzari M; Collins K; Yoshida A; Abouljoud MS; Moonka D
Gastroenterology; 2018 Nov; 155(5):1451-1462.e3. PubMed ID: 30056096
[TBL] [Abstract][Full Text] [Related]
10. The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.
Györi GP; Pereyra D; Rumpf B; Hackl H; Köditz C; Ortmayr G; Reiberger T; Trauner M; Berlakovich GA; Starlinger P
Hepatology; 2020 Aug; 72(2):584-594. PubMed ID: 31773739
[TBL] [Abstract][Full Text] [Related]
11. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort.
van Vugt JLA; Alferink LJM; Buettner S; Gaspersz MP; Bot D; Darwish Murad S; Feshtali S; van Ooijen PMA; Polak WG; Porte RJ; van Hoek B; van den Berg AP; Metselaar HJ; IJzermans JNM
J Hepatol; 2018 Apr; 68(4):707-714. PubMed ID: 29221886
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study.
Rodríguez-Perálvarez ML; Gómez-Orellana AM; Majumdar A; Bailey M; McCaughan GW; Gow P; Guerrero M; Taylor R; Guijo-Rubio D; Hervás-Martínez C; Tsochatzis EA
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):242-252. PubMed ID: 36528041
[TBL] [Abstract][Full Text] [Related]
13. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
Starlinger P; Ahn JC; Mullan A; Gyoeri GP; Pereyra D; Alva-Ruiz R; Hackl H; Reiberger T; Trauner M; Santol J; Simbrunner B; Mandorfer M; Berlakovich G; Kamath PS; Heimbach J
Hepatology; 2021 Sep; 74(3):1533-1545. PubMed ID: 33786862
[TBL] [Abstract][Full Text] [Related]
14. Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis.
Vitale A; Saracino E; D'Amico FE; Grigoletto F; Burra P; Angeli P; Boccagni P; Brolese A; Zanus G; Neri D; Gringeri E; D'Amico F; Valmasoni M; Carraro A; Gambato M; Feltracco P; Romano A; Buggio M; D'Amico DF; Cillo U
Transplant Proc; 2009 May; 41(4):1092-5. PubMed ID: 19460489
[TBL] [Abstract][Full Text] [Related]
15. Mortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (≤15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data.
Atiemo K; Skaro A; Maddur H; Zhao L; Montag S; VanWagner L; Goel S; Kho A; Ho B; Kang R; Holl JL; Abecassis MM; Levitsky J; Ladner DP
Am J Transplant; 2017 Sep; 17(9):2410-2419. PubMed ID: 28226199
[TBL] [Abstract][Full Text] [Related]
16. Model for end-stage liver disease and model for end-stage liver disease-Na scores predict both before-listing and wait-list mortality.
Yamashiki N; Sugawara Y; Tamura S; Kaneko J; Nojiri K; Aoki T; Sakamoto Y; Hasegawa K; Koike K; Kokudo N
Transplant Proc; 2012 Mar; 44(2):389-92. PubMed ID: 22410024
[TBL] [Abstract][Full Text] [Related]
17. Model for End-Stage Liver Disease-Sodium Score: The Evolution in the Prioritization of Liver Transplantation.
Machicao VI
Clin Liver Dis; 2017 May; 21(2):275-287. PubMed ID: 28364813
[TBL] [Abstract][Full Text] [Related]
18. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy.
Cejas NG; Villamil FG; Lendoire JC; Tagliafichi V; Lopez A; Krogh DH; Soratti CA; Bisigniano L
Liver Transpl; 2013 Jul; 19(7):711-20. PubMed ID: 23775946
[TBL] [Abstract][Full Text] [Related]
19. Revising model for end-stage liver disease from calendar-time cross-sections with correction for selection bias.
de Ferrante HC; van Rosmalen M; Smeulders BML; Vogelaar S; Spieksma FCR
BMC Med Res Methodol; 2024 Feb; 24(1):51. PubMed ID: 38419019
[TBL] [Abstract][Full Text] [Related]
20. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
